NCT00001189

Brief Summary

Patients with Grade I soft tissue sarcomas or benign, non-metastasizing invasive soft tissue tumors will receive wide local excision and be prospectively randomized as to either receive or not receive radiation therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Dec 1983

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 1983

Completed
15.9 years until next milestone

First Submitted

Initial submission to the registry

November 3, 1999

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2001

Completed
1.7 years until next milestone

First Posted

Study publicly available on registry

December 10, 2002

Completed
Last Updated

March 4, 2008

Status Verified

May 1, 2000

First QC Date

November 3, 1999

Last Update Submit

March 3, 2008

Conditions

SarcomaNeoplasms

Keywords

Adjuvant RadiotherapyLow-Grade SarcomaRadiotherapyRandomized StudySarcomaSurgery

Interventions

radiotherapyPROCEDURE

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
DISEASE CHARACTERISTICS: Biopsy-proven grade I soft tissue sarcoma or one of the following benign but highly invasive soft tissue tumors: Abdominal and extra-abdominal fibromatosis (desmoid, aggressive fibromatosis), Dermatofibrosarcoma protuberans, Intramuscular lipoma (infiltrating lipoma), Diffuse lipomatosis, Leiomyoma of deep soft tissue, Diffuse giant cell tumor of tendon sheath (proliferative synovitis). No clinical evidence of metastases in regional nodes or more distant sites. No primary intraperitoneal or retroperitoneal tumors. Resection of all gross tumor at the time of surgical excision required (margins may be pathologically positive or negative). No von Recklinghausen's disease. PRIOR/CONCURRENT THERAPY: Biologic Therapy: Not specified. Chemotherapy: No prior chemotherapy for sarcoma. Endocrine Therapy: Not specified. Radiotherapy: No prior radiotherapy for sarcoma. Surgery: No more than 4 months since definitive surgery for primary lesion or recurrence. No prior amputation. PATIENT CHARACTERISTICS: Age: 18 and over. Performance status: Not specified. Hematopoietic: Not specified. Hepatic: No cirrhosis. Renal: No evidence of severe renal impairment. Cardiovascular: No ischemic heart disease. OTHER: No prior malignancy except basal cell carcinoma. No serious infection. No active bleeding disorder. No severe concomitant disease.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

National Cancer Institute (NCI)

Bethesda, Maryland, 20892, United States

Location

Related Publications (1)

  • Wara WM, Phillips TL, Hill DR, Bovill E Jr, Luk KH, Lichter AS, Leibel SA. Desmoid tumors--treatment and prognosis. Radiology. 1977 Jul;124(1):225-6. doi: 10.1148/124.1.225.

    PMID: 405711BACKGROUND

MeSH Terms

Conditions

SarcomaNeoplasms

Interventions

Radiotherapy

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft TissueNeoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Therapeutics

Study Design

Study Type
interventional
Phase
phase 2
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

November 3, 1999

First Posted

December 10, 2002

Study Start

December 1, 1983

Study Completion

April 1, 2001

Last Updated

March 4, 2008

Record last verified: 2000-05

Locations

US(1)